Search

everythinglearnresearchcommunity

for

Search:↓

A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.

A user asked for opinions on a new hair supplement and whether it's better than Viviscal Pro. Another user responded, calling it useless.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

A 25-year-old male experienced hair regrowth after 4.5 months using a chewable treatment with 1mg finasteride, 6% minoxidil, and 2.5mg biotin, despite initial shedding and acne from accutane. Opinions on progress vary, with some noticing thicker hair and others seeing no difference or thinning.

The user experienced increased hair density and thickness after 3-4 months using finasteride, minoxidil, dermastamping, ketoconazole, and biotin. They apply minoxidil right after dermastamping without any side effects or shedding.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Castor oil's effectiveness for hair growth is debated, with concerns about its impact on skin health and prostaglandin levels. Some users suggest combining it with coconut oil and using it alongside finasteride for better results, while others recommend sticking to proven synthetic treatments.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.